Search 

Pharmaceutical

Biotech

Elasmogen, a next generation biologics company, develops soloMERs which are high affinity binding, single-domains; they are small (9% of an antibody), highly stable proteins and crucially are outside the complex/competitive antibody patent landscape. soloMERs are pre-disposed to generating potent neutralisers by binding to novel or cryptic epitopes. Their small size makes them ideal for both site-specific delivery and penetration of solid tumours. Our lead product, ADCP165, is an anti-ROR1 soloMER drug conjugate being co-developed with Almac Discovery. This program is tracking for entry into the clinic 2022/3 with follow on products in the pipeline. In addition our lead anti-auto-immune inflammatory domain, ELN/22, a tetravalent, bi-paratopic anti-TNF product is being developed for oral delivery for the treatment of IBD.
We are currently looking for partners for our existing assets and also companies who would like to access our powerful, patent protected soloMER platform to develop new products.

Innovative biologics for cancer and other patients' unmet needs

We are into Mabs - Biosimilars

Pharmaceutical

Pharmaceutical company

Medical Research and Development of innovative Products.Currently developed the Worlds 1st Hydroxychloroquine Sulfate based pMDI/ Medical micro dose as an Inhaler Therapeutic/Prophylactic to combat SARs CoVid2

Medical Device Company

Biopharmaceutical